Top Markets
#1 Pleasing Gold Pleasing Gold +1,049.05%
#2 PulseChain PulseChain +56.32%
#3 BOOK OF MEME BOOK OF MEME +39.77%
#4 DogBull DogBull +36.97%
#5 Ontology Gas Ontology Gas +31.77%
#6 Neiro Neiro +22.37%
#7 Unit Pump Unit Pump +21.94%
#8 Collect on Fanable Collect on Fanable +19.20%
#9 Pump.fun Pump.fun +18.98%
#10 rsERG rsERG +17.92%
Coin of the day
Pleasing Gold Pleasing Gold
Settings
Language
ENGLISH
Currency
USD
Theme
ProMIS Neurosciences, Inc. ProMIS Neurosciences, Inc.

ProMIS Neurosciences, Inc.

PMN
Rank in Stocks #26784
Based in Toronto, Canada, ProMIS Neurosciences, Inc. focuses on developing... Based in Toronto, Canada, ProMIS Neurosciences, Inc. focuses on developing precise medical solutions for severe neurodegenerative disorders, including Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company employs a unique discovery platform, which incorporates proprietary algorithms like ProMIS and Collective Coordinates, to identify novel, disease-specific targets, known as epitopes, located on the surface of misfolded proteins. The firm's primary product candidates include PMN310, a monoclonal antibody designed to combat toxic oligomers associated with Alzheimer's disease. Another candidate, PMN267, aims to target proteins such as superoxide dismutase 1 and TAR-DNA binding protein 43 relevant to ALS, as well as alpha-synuclein implicated in Parkinson's disease and Lewy body dementia. Additionally, PMN442 is a monoclonal antibody engineered to address toxic alpha-synuclein oligomers and seeding fibrils linked to MSA. Originally established in 2004, the company was known as Amorfix Life Sciences Ltd. before officially adopting the name ProMIS Neurosciences, Inc. in July 2015.
Share Price
$4.40
Last synced: 2023-07-21
Market Cap
$37.78M
Change (1 day)
-7.03%
Change (1 year)
0.00%
Country
CA
Trade ProMIS Neurosciences, Inc. (PMN)

Category

Healthcare
P/E ratio for ProMIS Neurosciences, Inc. (PMN)
P/E ratio as of 2026 TTM: 0
According to ProMIS Neurosciences, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for ProMIS Neurosciences, Inc. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.